Physician profile
Caryn Bray
NPI 1962498923
$2,797.28
in general payments reported to CMS, 2019-2025
31 companies · $436 in 2025
The $436 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $95.07 · 2021: $241 · 2022: $563 · 2023: $628 · 2024: $404 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.06 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.93 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $274.22 | 2023 | Ova1 |
| Astellas Pharma US INC | $256.71 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $246.63 | 2021-2025 | |
| Pfizer INC. | $171.77 | 2019-2024 | |
| Medtronic, INC. | $134.20 | 2022 | |
| Hologic Sales and Service, LLC | $125.94 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Millicent US INC | $110.59 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $103.54 | 2019-2024 | Slynd |
| Therapeuticsmd, INC. | $78.82 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $72.42 | 2019-2020 | |
| Novo Nordisk INC | $67.13 | 2020-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $58.88 | 2023 | Myfembree |
| Shield Therapeutics INC | $55.87 | 2024-2025 | |
| Myovant Sciences INC. | $53.85 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $53.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.19 | 2023-2025 | |
| Scynexis, INC. | $33.36 | 2022 | |
| Coopersurgical, INC. | $33.17 | 2019-2025 | Ally II Ups |
| Amag Pharmaceuticals, INC. | $29.89 | 2019-2020 | |
| Teleflex LLC | $28.61 | 2025 | Quikclot |
| Roche Diagnostics Corporation | $27.06 | 2022 | |
| Ascend Therapeutics US, LLC | $23.68 | 2022 | |
| Bsn Medical INC | $22.03 | 2025 | |
| Gynesonics, INC. | $17.61 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.13 | 2019 | |
| Agile Therapeutics, INC. | $15.46 | 2024 | Twirla |
| Exact Sciences Corporation | $14.95 | 2025 | Cologuard Collection Kit |
| Organon LLC | $13.00 | 2025 | Jada System |
| Boston Scientific Corporation | $12.59 | 2019 | |
| Meditrina | $10.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.